RE:RE:RE:Wino is MIA? We must have closure on some partners, joint R&D projects or a rapid drug acquisition to stimulate sales. What are they doing? I suspect the internal sales team is presently busy lowering their golf handicap this summer. Creating an internal sales force was only a good thing if they are swamped. Not just busy but swamped. We brought all the costs in house, but for what?
jfm1330 wrote: Same for me, I did not comment because there is nothing interesting to comment about. The story is repeating itself with Thera, and Levesque looks more and more like a new John Huss. He is now doing the same thing Huss did back around 2011, laying off R&D employees to cover his failures as CEO. So speciality pharmacies were expecting a higher demand with Egrifta and Trogarzo, but thanks to our great marketing department, Thera was unable to deliver on those expectations. With Thera always expect mild failures, that's why they still exist as a company. They never achieve real commercial success and more often than not miis on their own guidance. It's the same story with this company, the R&D side delivers, but the rest is not as good, and the first to pay are the R&D people, always. Their failure to come up with a good protocol for phase I of TH1902 cost the jobs of many scientists there. Levesque said he was in discussions with companies interested to develop new PDC with TH19P01 and their own cytotoxic agents. Who will do this work now that he closed the R&D lab? What about new PDCs with SN38, other cytotoxic agents or siRNA? All that is on hold at best. So nothing positive to talk about. My level of trust in this management is very low now. Levesque looks like a bad BS artist than anything else. He is unable to deliver on anything. It's all promises, no accomplishments. Their credibility problem is deeper than ever.